Clinical experience with using lacosamide for the treatment of epilepsy in a tertiary centre

Acta Neurologica Scandinavica

Volumn 127, Issue 3, 2013, Pages 149-153

  Kamel, J T ^a   Degruyter, M A ^a   D'Souza, W J ^a   Cook, M J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antiepileptic drugs; Lacosamide; Lamotrigine; Sodium channel blocking agent

Indexed keywords

HARKOSERIDE; LAMOTRIGINE; SODIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMARKETING SURVEILLANCE; SEDATION; SIDE EFFECT; TERTIARY HEALTH CARE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; SODIUM CHANNEL BLOCKERS; YOUNG ADULT;

EID: 84873994405     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2012.01704.x     Document Type: Article

References (11)

1. Curia G, Biagini G, Perucca E, Avoli M. Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs 2009;23:555-68.
2. Kelemen A, Halász P. Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychiatr Dis Treat 2010;6:465-71.
3. Beydoun A, D'Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9:33-42.
4. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 2009;5:757-66.
5. Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures - cost utility results for Sweden. Acta Neurol Scand 2010;121:406-12.
6. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol 2010;50:459-71.
7. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011;20:20-3.
8. Chung S, Ben-Menachem E, Sperling MR et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 2010;24:1041-54.
9. Wehner T, Bauer S, Hamer HM et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009;16:423-5.
10. Stephen LJ, Kelly K, Parker P, Brodie MJ. Adjunctive lacosamide in clinical practice: sodium blockade with a difference? Epilepsy Behav 2011;22:499-504.
11. Sake J, Hebert D, Isojärvi J et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010;24:1055-68.